The Asia-Pacific neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). China, India, and Japan, are the key economies contributing to the Asia-Pacific neurological disorder drugs industry growth. The key factors that primarily drive the market growth include the rising prevalence of neurological disorders and key contributions by the key players.
Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in novel drug development and innovation. The rising elder population over 65 years of age is the prime factor that creates scope for the growth of the Asia-Pacific neurological disorder drugs market as this population pool is at high risk of developing neurological disorders such as Parkinson’s Disease, and Alzheimer’s Disease.
Browse the full report description of "Asia-Pacific Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/asia-pacific-neurological-disorder-drugs-market
As per the World Bank 2019, Japan has around 28.0% geriatric population, China has 11.4%, Thailand has 12.4%, Singapore has 12.4%, while India has a total of 6.4% population aged 65 and over. As elder people are more prone to diseases, hence, creates a wide scope for the market growth in the region.
Besides, the presence of the key players such as Cadila Healthcare Ltd., Astellas Pharma Ltd., and Cipla Ltd., among others are also contributing to the growth of the market.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID-19
o Most affected segment
Asia-Pacific Neurological Disorder Drugs Market – Segmentation
By Disorder Type
Asia-Pacific Neurological Disorder Drugs Market – Countries Covered
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-neurological-disorder-drugs-market